Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions to Participate in Investor Conferences

GlobeNewswire January 3, 2022

Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

GlobeNewswire December 16, 2021

SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600

PR Newswire November 22, 2021

Emergent BioSolutions Announces Stock Repurchase Program

GlobeNewswire November 11, 2021

Emergent BioSolutions Reports Financial Results For Third Quarter 2021

GlobeNewswire November 4, 2021

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

GlobeNewswire November 2, 2021

Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021

GlobeNewswire October 18, 2021

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

GlobeNewswire October 15, 2021

Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.

Business Wire September 21, 2021

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

GlobeNewswire September 14, 2021

Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

GlobeNewswire August 25, 2021

Emergent BioSolutions to Participate in Investor Conferences

GlobeNewswire August 23, 2021

Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector

GlobeNewswire October 4, 2017

Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent BioSolutions, Inc., Frontier Communications Corporation, HSN, Inc., Insys Therapeutics Inc., LSB Industries, Inc. and Otonomy, Inc.

PR Newswire October 3, 2017

Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK

GlobeNewswire October 3, 2017

Emergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit Facility

GlobeNewswire October 2, 2017

Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 Million

GlobeNewswire September 25, 2017

Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure

GlobeNewswire September 18, 2017

Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance

GlobeNewswire August 3, 2017

Investor Network: Emergent BioSolutions Inc. to Host Earnings Call

Accesswire August 3, 2017